An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized TrialMasahiro Natsuaki, Takeshi Kimura, Kenji Andò et al.|Circulation|2023Cited by 145
SREBP-1 Interacts with Hepatocyte Nuclear Factor-4α and Interferes with PGC-1 Recruitment to Suppress Hepatic Gluconeogenic GenesTakashi Yamamoto, Nobuhiro Yamada|Journal of Biological Chemistry|2004Cited by 141
Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trialHirotoshi Watanabe, Takeshi Kimura, Masahiro Natsuaki et al.|European Heart Journal|2024Cited by 37